Latest Genzyme Stories
NOVATO, Calif., Sept. 13, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 2011 at 12:30 p.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one...
NOVATO, Calif., Sept. 7, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 14, 2011 at 10:55 a.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the...
CARLSBAD, Calif., Sept. 6, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast: Data from Mipomersen's Open-Label Extension Study What: presented at ESC Wednesday, September 07, 2011 at 12:00 p.m. ET /9:00 When: a.m. PT Where: www.isispharm.com Live on the Internet. Simply log onto our Web site How: listed above. If you are...
SOUTH PLAINFIELD, N.J. and CAMBRIDGE, Mass., Sept. 2, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration. Under the original agreement, PTC held commercial rights for the U.S. and Canada and Genzyme held commercial rights in all other countries. Under the restructured agreement, PTC regains worldwide rights to ataluren and Genzyme retains an option to commercialize ataluren in indications other than nonsense...
NOVATO, Calif., Aug. 30, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Baird Health Care Conference in New York on Wednesday, September 7, 2011 at 9:30 a.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week...
NOVATO, Calif., Aug. 9, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wedbush Life Sciences Conference in New York on Tuesday, August 16, 2011 at 10:00 a.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one...
CARLSBAD, Calif., Aug. 4, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended June 30, 2011. The Company finished the second quarter of 2011 with a pro forma net operating loss (NOL) of $11.6 million and $24.9 million for the three and six months ended June 30, 2011, respectively, compared to a pro forma NOL of $15.5 million and $17.1 million for the same periods in 2010. The Company finished the second quarter of 2011...
TUCSON, Ariz., Aug. 1, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today the appointment of Mara Aspinall to the role of President, Ventana Medical Systems, Inc. Aspinall was most recently Founder, President, and CEO of On-Q-ity, a start-up diagnostics company focused on circulating tumor cell technology. (Photo: http://photos.prnewswire.com/prnh/20110801/LA44346) Prior to this, Aspinall spent twelve years with Genzyme Corporation...
NOVATO, Calif., July 28, 2011 /PRNewswire/ -- Financial Highlights ($ in millions, except per share data, unaudited) Item Q2 2011 Total BioMarin Revenue $110.6 Total Net Product Revenue $109.6 Naglazyme Net Product Revenue $60.3 Aldurazyme BioMarin Net Product Revenue* $17.3 Kuvan Net...
PARIS, July 28, 2011 /PRNewswire/ -- (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Change on Q2 2011 a Change at ------- Reported Constant exchange basis rates(1) euro Net sales 8,349m +0.5% +6.9%...
